{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:48:38Z","timestamp":1771710518859,"version":"3.50.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["10854179"],"award-info":[{"award-number":["10854179"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The migraine premonitory phase is characterized in part by increased thirst, urination and yawning. Imaging studies show that the hypothalamus is activated in the premonitory phase. Stress is a well know migraine initiation factor which was demonstrated to engage dynorphin\/kappa opioid receptors (KOR) signaling in several brain regions, including the hypothalamus. This study proposes the exploration of the possible link between hypothalamic KOR and migraine premonitory symptoms in rodent models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Rats were treated systemically with the KOR agonist U-69,593 followed by yawning and urination monitoring. Apomorphine, a dopamine D1\/2 agonist, was used as a positive control for yawning behaviors. Urination and water consumption following systemic administration of U-69,593 was also assessed. To examine if KOR activation specifically in the hypothalamus can promote premonitory symptoms, AAV8-hSyn-DIO-hM4Di (Gi-DREADD)-mCherry viral vector was microinjected into the right arcuate nucleus (ARC) of female and male KOR<jats:sup>CRE<\/jats:sup> or KOR<jats:sup>WT<\/jats:sup> mice. Four weeks after the injection, clozapine N-oxide (CNO) was administered systemically followed by the assessment of urination, water consumption and tactile sensory response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Systemic administration of U-69,593 increased urination but did not produce yawning in rats. Systemic KOR agonist also increased urination in mice as well as water consumption. Cell specific Gi-DREADD activation (i.e., inhibition through Gi-coupled signaling) of KOR<jats:sup>CRE<\/jats:sup> neurons in the ARC also increased water consumption and the total volume of urine in mice but did not affect tactile sensory responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our studies in rodents identified the KOR in a hypothalamic region as a mechanism that promotes behaviors consistent with clinically-observed premonitory symptoms of migraine, including increased thirst and urination but not yawning. Importantly, these behaviors occurred in the absence of pain responses, consistent with the emergence of the premonitory phase before the headache phase. Early intervention for preventive treatment even before the headache phase may be achievable by targeting the hypothalamic KOR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01497-7","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:04:02Z","timestamp":1664492642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exploring the neurobiology of the premonitory phase of migraine preclinically \u2013 a role for hypothalamic kappa opioid receptors?"],"prefix":"10.1186","volume":"23","author":[{"given":"Caroline M.","family":"Kopruszinski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robson","family":"Vizin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley L.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Henrique Moreira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edita","family":"Navratilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"issue":"5","key":"1497_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.neuron.2018.01.029","volume":"97","author":"KC Brennan","year":"2018","unstructured":"Brennan KC, Pietrobon D (2018) A systems neuroscience approach to migraine. Neuron 97(5):1004\u20131021. https:\/\/doi.org\/10.1016\/j.neuron.2018.01.029","journal-title":"Neuron"},{"issue":"Suppl 1","key":"1497_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/head.13300","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) A phase-by-phase review of migraine pathophysiology. Headache 58(Suppl 1):4\u201316. https:\/\/doi.org\/10.1111\/head.13300","journal-title":"Headache"},{"issue":"12","key":"1497_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","volume":"14","author":"N Karsan","year":"2018","unstructured":"Karsan N, Goadsby PJ (2018) Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 14(12):699\u2013710. https:\/\/doi.org\/10.1038\/s41582-018-0098-4","journal-title":"Nat Rev Neurol"},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fneur.2020.00140","volume":"11","author":"N Karsan","year":"2020","unstructured":"Karsan N, Goadsby PJ (2020) Imaging the premonitory phase of migraine. Front Neurol 11:140. https:\/\/doi.org\/10.3389\/fneur.2020.00140","journal-title":"Front Neurol"},{"issue":"Pt 7","key":"1497_CR5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/brain\/aww097","volume":"139","author":"LH Schulte","year":"2016","unstructured":"Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139(Pt 7):1987\u20131993. https:\/\/doi.org\/10.1093\/brain\/aww097","journal-title":"Brain"},{"issue":"9","key":"1497_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1468-2982.2006.01157.x","volume":"26","author":"E Quintela","year":"2006","unstructured":"Quintela E, Castillo J, Munoz P, Pascual J (2006) Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia 26(9):1051\u20131060. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01157.x","journal-title":"Cephalalgia"},{"issue":"10","key":"1497_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/j.1468-2982.2006.01195.x","volume":"26","author":"GG Schoonman","year":"2006","unstructured":"Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD (2006) The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 26(10):1209\u20131213. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01195.x","journal-title":"Cephalalgia"},{"issue":"4","key":"1497_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1046\/j.1468-2982.1985.0504223.x","volume":"5","author":"J Waelkens","year":"1985","unstructured":"Waelkens J (1985) Warning symptoms in migraine: characteristics and therapeutic implications. Cephalalgia 5(4):223\u2013228. https:\/\/doi.org\/10.1046\/j.1468-2982.1985.0504223.x","journal-title":"Cephalalgia"},{"issue":"2","key":"1497_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.nic.2019.01.009","volume":"29","author":"BM Ellingson","year":"2019","unstructured":"Ellingson BM, Hesterman C, Johnston M, Dudeck NR, Charles AC, Villablanca JP (2019) Advanced imaging in the evaluation of migraine headaches. Neuroimaging Clin N Am 29(2):301\u2013324. https:\/\/doi.org\/10.1016\/j.nic.2019.01.009","journal-title":"Neuroimaging Clin N Am"},{"issue":"5","key":"1497_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/head.12572","volume":"55","author":"FH Maniyar","year":"2015","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin CJ, Goadsby PJ (2015) The premonitory phase of migraine\u2013what can we learn from it? Headache 55(5):609\u2013620. https:\/\/doi.org\/10.1111\/head.12572","journal-title":"Headache"},{"issue":"1","key":"1497_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-018-0844-4","volume":"19","author":"PR Holland","year":"2018","unstructured":"Holland PR, Barloese M, Fahrenkrug J (2018) PACAP in hypothalamic regulation of sleep and circadian rhythm: importance for headache. J Headache Pain 19(1):20. https:\/\/doi.org\/10.1186\/s10194-018-0844-4","journal-title":"J Headache Pain"},{"issue":"1","key":"1497_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-020-1079-8","volume":"21","author":"K Warfvinge","year":"2020","unstructured":"Warfvinge K, Krause D, Edvinsson L (2020) The distribution of oxytocin and the oxytocin receptor in rat brain: relation to regions active in migraine. J Headache Pain 21(1):10. https:\/\/doi.org\/10.1186\/s10194-020-1079-8","journal-title":"J Headache Pain"},{"issue":"2","key":"1497_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"issue":"Pt 1","key":"1497_CR14","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/brain\/awt320","volume":"137","author":"FH Maniyar","year":"2014","unstructured":"Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137(Pt 1):232\u2013241. https:\/\/doi.org\/10.1093\/brain\/awt320","journal-title":"Brain"},{"issue":"Suppl 1","key":"1497_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10072-017-2866-0","volume":"38","author":"A May","year":"2017","unstructured":"May A (2017) Understanding migraine as a cycling brain syndrome: reviewing the evidence from functional imaging. Neurol Sci 38(Suppl 1):125\u2013130. https:\/\/doi.org\/10.1007\/s10072-017-2866-0","journal-title":"Neurol Sci"},{"issue":"7","key":"1497_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nm0795-658","volume":"1","author":"C Weiller","year":"1995","unstructured":"Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1(7):658\u2013660. https:\/\/doi.org\/10.1038\/nm0795-658","journal-title":"Nat Med"},{"issue":"11","key":"1497_CR17","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1172\/JCI43766","volume":"120","author":"MH Ossipov","year":"2010","unstructured":"Ossipov MH, Dussor GO, Porreca F (2010) Central modulation of pain. J Clin Invest 120(11):3779\u20133787. https:\/\/doi.org\/10.1172\/JCI43766","journal-title":"J Clin Invest"},{"issue":"2","key":"1497_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuron.2012.01.001","volume":"73","author":"D Borsook","year":"2012","unstructured":"Borsook D, Maleki N, Becerra L, McEwen B (2012) Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron 73(2):219\u2013234. https:\/\/doi.org\/10.1016\/j.neuron.2012.01.001","journal-title":"Neuron"},{"issue":"16","key":"1497_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1212\/WNL.0000000000000332","volume":"82","author":"RB Lipton","year":"2014","unstructured":"Lipton RB, Buse DC, Hall CB, Tennen H, Defreitas TA, Borkowski TM, Grosberg BM, Haut SR (2014) Reduction in perceived stress as a migraine trigger: testing the \u201clet-down headache\u201d hypothesis. Neurology 82(16):1395\u20131401. https:\/\/doi.org\/10.1212\/WNL.0000000000000332","journal-title":"Neurology"},{"issue":"Suppl 2","key":"1497_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1526-4610.2012.02241.x","volume":"52","author":"N Maleki","year":"2012","unstructured":"Maleki N, Becerra L, Borsook D (2012) Migraine: maladaptive brain responses to stress. Headache 52(Suppl 2):102\u2013106. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02241.x","journal-title":"Headache"},{"issue":"8","key":"1497_CR21","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/0333102417702120","volume":"37","author":"JY Xie","year":"2017","unstructured":"Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F (2017) Kappa opioid receptor antagonists: a possible new class of therapeutics for migraine prevention. Cephalalgia 37(8):780\u2013794. https:\/\/doi.org\/10.1177\/0333102417702120","journal-title":"Cephalalgia"},{"issue":"2","key":"1497_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00213-010-1806-y","volume":"210","author":"MR Bruchas","year":"2010","unstructured":"Bruchas MR, Chavkin C (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology 210(2):137\u2013147. https:\/\/doi.org\/10.1007\/s00213-010-1806-y","journal-title":"Psychopharmacology"},{"key":"1497_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2009.08.062","volume":"1314","author":"MR Bruchas","year":"2010","unstructured":"Bruchas MR, Land BB, Chavkin C (2010) The dynorphin\/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314:44\u201355. https:\/\/doi.org\/10.1016\/j.brainres.2009.08.062","journal-title":"Brain Res"},{"issue":"3","key":"1497_CR24","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/0333102420959794","volume":"41","author":"CM Kopruszinski","year":"2021","unstructured":"Kopruszinski CM, Navratilova E, Swiokla J, Dodick DW, Chessell IP, Porreca F (2021) A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. Cephalalgia 41(3):305\u2013317. https:\/\/doi.org\/10.1177\/0333102420959794","journal-title":"Cephalalgia"},{"issue":"4","key":"1497_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/mcne.1994.1039","volume":"5","author":"AM DePaoli","year":"1994","unstructured":"DePaoli AM, Hurley KM, Yasada K, Reisine T, Bell G (1994) Distribution of kappa opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study. Mol Cell Neurosci 5(4):327\u2013335. https:\/\/doi.org\/10.1006\/mcne.1994.1039","journal-title":"Mol Cell Neurosci"},{"issue":"3","key":"1497_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pharmthera.2009.05.006","volume":"123","author":"C Schwarzer","year":"2009","unstructured":"Schwarzer C (2009) 30 years of dynorphins\u2013new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123(3):353\u2013370. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.05.006","journal-title":"Pharmacol Ther"},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1314.001","volume":"1032","author":"BS McEwen","year":"2004","unstructured":"McEwen BS (2004) Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci 1032:1\u20137. https:\/\/doi.org\/10.1196\/annals.1314.001","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"1497_CR28","doi-asserted-by":"publisher","first-page":"17180","DOI":"10.1073\/pnas.1121254109","volume":"109","author":"BS McEwen","year":"2012","unstructured":"McEwen BS (2012) Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A 109(Suppl 2):17180\u201317185. https:\/\/doi.org\/10.1073\/pnas.1121254109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1497_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cne.902490302","volume":"249","author":"JH Fallon","year":"1986","unstructured":"Fallon JH, Leslie FM (1986) Distribution of dynorphin and enkephalin peptides in the rat brain. J Comp Neurol 249(3):293\u2013336. https:\/\/doi.org\/10.1002\/cne.902490302","journal-title":"J Comp Neurol"},{"key":"1497_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac104","author":"M Watanabe","year":"2022","unstructured":"Watanabe M, Kopruszinski CM, Moutal A, Ikegami D, Khanna R, Chen Y, Ross S, Mackenzie K, Stratton J, Dodick DW, Navratilova E, Porreca F (2022) Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain. https:\/\/doi.org\/10.1093\/brain\/awac104","journal-title":"Brain"},{"issue":"1","key":"1497_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/dvg.22910","volume":"54","author":"X Cai","year":"2016","unstructured":"Cai X, Huang H, Kuzirian MS, Snyder LM, Matsushita M, Lee MC, Ferguson C, Homanics GE, Barth AL, Ross SE (2016) Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signaling. Genesis 54(1):29\u201337. https:\/\/doi.org\/10.1002\/dvg.22910","journal-title":"Genesis"},{"issue":"3","key":"1497_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0163-1047(92)90454-c","volume":"58","author":"MJ Cambiasso","year":"1992","unstructured":"Cambiasso MJ, Chiaraviglio E (1992) The involvement of the hypothalamic preoptic area on the regulation of thirst in the rat. Behav Neural Biol 58(3):190\u2013195. https:\/\/doi.org\/10.1016\/0163-1047(92)90454-c","journal-title":"Behav Neural Biol"},{"issue":"1","key":"1497_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cne.20786","volume":"493","author":"JK Elmquist","year":"2005","unstructured":"Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB (2005) Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 493(1):63\u201371. https:\/\/doi.org\/10.1002\/cne.20786","journal-title":"J Comp Neurol"},{"issue":"7063","key":"1497_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/nature04284","volume":"437","author":"CB Saper","year":"2005","unstructured":"Saper CB, Scammell TE, Lu J (2005) Hypothalamic regulation of sleep and circadian rhythms. Nature 437(7063):1257\u20131263. https:\/\/doi.org\/10.1038\/nature04284","journal-title":"Nature"},{"issue":"5 Suppl 1","key":"1497_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0090-4295(01)01633-8","volume":"59","author":"BF Blok","year":"2002","unstructured":"Blok BF (2002) Central pathways controlling micturition and urinary continence. Urology 59(5 Suppl 1):13\u201317. https:\/\/doi.org\/10.1016\/s0090-4295(01)01633-8","journal-title":"Urology"},{"issue":"2","key":"1497_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0166-4328(97)00184-8","volume":"92","author":"BF Blok","year":"1998","unstructured":"Blok BF, Holstege G (1998) The central nervous system control of micturition in cats and humans. Behav Brain Res 92(2):119\u2013125. https:\/\/doi.org\/10.1016\/s0166-4328(97)00184-8","journal-title":"Behav Brain Res"},{"issue":"5","key":"1497_CR37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/j.pain.0000000000001791","volume":"161","author":"A Melo-Carrillo","year":"2020","unstructured":"Melo-Carrillo A, Schain AJ, Stratton J, Strassman AM, Burstein R (2020) Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier. Pain 161(5):1037\u20131043. https:\/\/doi.org\/10.1097\/j.pain.0000000000001791","journal-title":"Pain"},{"issue":"4580","key":"1497_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1126\/science.6129699","volume":"219","author":"R Przewlocki","year":"1983","unstructured":"Przewlocki R, Lason W, Konecka AM, Gramsch C, Herz A, Reid LD (1983) The opioid peptide dynorphin, circadian rhythms, and starvation. Science 219(4580):71\u201373. https:\/\/doi.org\/10.1126\/science.6129699","journal-title":"Science"},{"issue":"2","key":"1497_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/head.13195","volume":"58","author":"B Guven","year":"2018","unstructured":"Guven B, Guven H, Comoglu SS (2018) Migraine and Yawning. Headache 58(2):210\u2013216. https:\/\/doi.org\/10.1111\/head.13195","journal-title":"Headache"},{"issue":"2","key":"1497_CR40","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1590\/s0004-282x1994000200023","volume":"52","author":"F Aloe","year":"1994","unstructured":"Aloe F (1994) Yawning. Arq Neuropsiquiatr 52(2):273\u2013276. https:\/\/doi.org\/10.1590\/s0004-282x1994000200023","journal-title":"Arq Neuropsiquiatr"},{"issue":"Suppl 6","key":"1497_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/03331024870070S641","volume":"7","author":"A Argiolas","year":"1987","unstructured":"Argiolas A, Melis MR, Gessa GL (1987) Yawning: neurochemistry, physiology and pathology. Cephalalgia 7(Suppl 6):131\u2013137. https:\/\/doi.org\/10.1177\/03331024870070S641","journal-title":"Cephalalgia"},{"key":"1497_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000307085","volume":"28","author":"GT Collins","year":"2010","unstructured":"Collins GT, Eguibar JR (2010) Neurophamacology of yawning. Front Neurol Neurosci 28:90\u2013106. https:\/\/doi.org\/10.1159\/000307085","journal-title":"Front Neurol Neurosci"},{"issue":"3","key":"1497_CR43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/BF02246550","volume":"122","author":"MR Zarrindast","year":"1995","unstructured":"Zarrindast MR, Fatehi F, Mohagheghi-Badi M (1995) Effects of adenosine agents on apomorphine-induced yawning in rats. Psychopharmacology 122(3):292\u2013296. https:\/\/doi.org\/10.1007\/BF02246550","journal-title":"Psychopharmacology"},{"issue":"19","key":"1497_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1523\/JNEUROSCI.21-19-j0003.2001","volume":"21","author":"TC Chou","year":"2001","unstructured":"Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT, Beuckmann CT, Chemelli RM, Sakurai T, Yanagisawa M, Saper CB, Scammell TE (2001) Orexin (hypocretin) neurons contain dynorphin. J Neurosci 21(19):168","journal-title":"J Neurosci"},{"issue":"50","key":"1497_CR45","doi-asserted-by":"publisher","first-page":"13037","DOI":"10.1523\/JNEUROSCI.3380-06.2006","volume":"26","author":"Y Li","year":"2006","unstructured":"Li Y, van den Pol AN (2006) Differential target-dependent actions of coexpressed inhibitory dynorphin and excitatory hypocretin\/orexin neuropeptides. J Neurosci 26(50):13037\u201313047. https:\/\/doi.org\/10.1523\/JNEUROSCI.3380-06.2006","journal-title":"J Neurosci"},{"issue":"16","key":"1497_CR46","doi-asserted-by":"publisher","first-page":"E1648","DOI":"10.1073\/pnas.1315542111","volume":"111","author":"JW Muschamp","year":"2014","unstructured":"Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, Kamenecka TM, Borgland SL, Kenny PJ, Carlezon WA Jr (2014) Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A 111(16):E1648-1655. https:\/\/doi.org\/10.1073\/pnas.1315542111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1497_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/pl00004989","volume":"355","author":"MR Melis","year":"1997","unstructured":"Melis MR, Succu S, Iannucci U, Argiolas A (1997) Prevention by morphine of apomorphine- and oxytocin-induced penile erection and yawning: involvement of nitric oxide. Naunyn Schmiedebergs Arch Pharmacol 355(5):595\u2013600. https:\/\/doi.org\/10.1007\/pl00004989","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1497_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0006-8993(03)02938-x","volume":"982","author":"MC Ko","year":"2003","unstructured":"Ko MC, Willmont KJ, Lee H, Flory GS, Woods JH (2003) Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys. Brain Res 982(1):38\u201344. https:\/\/doi.org\/10.1016\/s0006-8993(03)02938-x","journal-title":"Brain Res"},{"issue":"1","key":"1497_CR49","first-page":"89","volume":"224","author":"JD Leander","year":"1983","unstructured":"Leander JD (1983) A kappa opioid effect: increased urination in the rat. J Pharmacol Exp Ther 224(1):89\u201394","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1497_CR50","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1152\/ajpregu.00863.2006","volume":"293","author":"W Qi","year":"2007","unstructured":"Qi W, Ebenezar KK, Samhan MA, Smith FG (2007) Renal responses to the kappa-opioid-receptor agonist U-50488H in conscious lambs. Am J Physiol Regul Integr Comp Physiol 293(1):R162-168. https:\/\/doi.org\/10.1152\/ajpregu.00863.2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"1497_CR51","first-page":"641","volume":"230","author":"GR Slizgi","year":"1984","unstructured":"Slizgi GR, Taylor CJ, Ludens JH (1984) Effects of the highly selective kappa opioid, U-50, 488, on renal function in the anesthetized dog. J Pharmacol Exp Ther 230(3):641\u2013645","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1497_CR52","first-page":"232","volume":"278","author":"E Bellissant","year":"1996","unstructured":"Bellissant E, Denolle T, Sinnassamy P, Bichet DG, Giudicelli JF, Lecoz F, Gandon JM, Allain H (1996) Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunteers. J Pharmacol Exp Ther 278(1):232\u2013242","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1497_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0168-8278(00)80187-7","volume":"32","author":"A Gadano","year":"2000","unstructured":"Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D (2000) Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 32(1):38\u201342. https:\/\/doi.org\/10.1016\/s0168-8278(00)80187-7","journal-title":"J Hepatol"},{"issue":"3","key":"1497_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1365-2125.2000.00256.x","volume":"50","author":"HJ Kramer","year":"2000","unstructured":"Kramer HJ, Uhl W, Ladstetter B, Backer A (2000) Influence of asimadoline, a new kappa-opioid receptor agonist, on tubular water absorption and vasopressin secretion in man. Br J Clin Pharmacol 50(3):227\u2013235. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00256.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1497_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1210\/jcem-62-1-181","volume":"62","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Braun S, Mann K, Meyer HD, Brantl V (1986) Anterior pituitary hormone responses to a kappa-opioid agonist in man. J Clin Endocrinol Metab 62(1):181\u2013185. https:\/\/doi.org\/10.1210\/jcem-62-1-181","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1497_CR56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1365-2125.1991.tb03960.x","volume":"32","author":"GH Rimoy","year":"1991","unstructured":"Rimoy GH, Bhaskar NK, Wright DM, Rubin PC (1991) Mechanism of diuretic action of spiradoline (U-62066E)\u2013a kappa opioid receptor agonist in the human. Br J Clin Pharmacol 32(5):611\u2013615. https:\/\/doi.org\/10.1111\/j.1365-2125.1991.tb03960.x","journal-title":"Br J Clin Pharmacol"},{"key":"1497_CR57","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/164_2020_399","volume":"271","author":"S Inan","year":"2022","unstructured":"Inan S (2022) Kappa opioid agonist-induced diuresis: characteristics, mechanisms, and beyond. Handb Exp Pharmacol 271:401\u2013417. https:\/\/doi.org\/10.1007\/164_2020_399","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"1497_CR58","doi-asserted-by":"publisher","first-page":"R1289","DOI":"10.1152\/ajpregu.00302.2005","volume":"289","author":"HB Gottlieb","year":"2005","unstructured":"Gottlieb HB, Kapusta DR (2005) Endogenous central kappa-opioid systems augment renal sympathetic nerve activity to maximally retain urinary sodium during hypotonic saline volume expansion. Am J Physiol Regul Integr Comp Physiol 289(5):R1289-1296. https:\/\/doi.org\/10.1152\/ajpregu.00302.2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"1497_CR59","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00210-008-0358-8","volume":"379","author":"S Inan","year":"2009","unstructured":"Inan S, Lee DY, Liu-Chen LY, Cowan A (2009) Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A. Naunyn Schmiedebergs Arch Pharmacol 379(3):263\u2013270. https:\/\/doi.org\/10.1007\/s00210-008-0358-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2 Pt 1","key":"1497_CR60","doi-asserted-by":"publisher","first-page":"E367","DOI":"10.1152\/ajpendo.1996.270.2.E367","volume":"270","author":"NF Rossi","year":"1996","unstructured":"Rossi NF, Brooks DP (1996) kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites. Am J Physiol 270(2 Pt 1):E367-372. https:\/\/doi.org\/10.1152\/ajpendo.1996.270.2.E367","journal-title":"Am J Physiol"},{"issue":"3\u20134","key":"1497_CR61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000181811","volume":"34","author":"G Hamon","year":"1990","unstructured":"Hamon G, Jouquey S (1990) Kappa agonists and vasopressin secretion. Horm Res 34(3\u20134):129\u2013132. https:\/\/doi.org\/10.1159\/000181811","journal-title":"Horm Res"},{"issue":"2","key":"1497_CR62","first-page":"463","volume":"234","author":"JD Leander","year":"1985","unstructured":"Leander JD, Zerbe RL, Hart JC (1985) Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J Pharmacol Exp Ther 234(2):463\u2013469","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1497_CR63","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000125078","volume":"48","author":"Y Oiso","year":"1988","unstructured":"Oiso Y, Iwasaki Y, Kondo K, Takatsuki K, Tomita A (1988) Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis. Neuroendocrinology 48(6):658\u2013662. https:\/\/doi.org\/10.1159\/000125078","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1497_CR64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1677\/joe.0.1290411","volume":"129","author":"T Wells","year":"1991","unstructured":"Wells T, Forsling ML (1991) Kappa-opioid modulation of vasopressin secretion in conscious rats. J Endocrinol 129(3):411\u2013416. https:\/\/doi.org\/10.1677\/joe.0.1290411","journal-title":"J Endocrinol"},{"issue":"4","key":"1497_CR65","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1476-5381.1994.tb17142.x","volume":"113","author":"A Barber","year":"1994","unstructured":"Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, Mauler F, Minck KO, Murray RD, Simon M et al (1994) A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753. Br J Pharmacol 113(4):1317\u20131327. https:\/\/doi.org\/10.1111\/j.1476-5381.1994.tb17142.x","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1497_CR66","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1476-5381.1994.tb14815.x","volume":"111","author":"A Barber","year":"1994","unstructured":"Barber A, Bartoszyk GD, Greiner HE, Mauler F, Murray RD, Seyfried CA, Simon M, Gottschlich R, Harting J, Lues I (1994) Central and peripheral actions of the novel kappa-opioid receptor agonist, EMD 60400. Br J Pharmacol 111(3):843\u2013851. https:\/\/doi.org\/10.1111\/j.1476-5381.1994.tb14815.x","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1497_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph12020095","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonists. Pharmaceuticals (Basel) 12(2):95. https:\/\/doi.org\/10.3390\/ph12020095","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"1497_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/medsci7090093","volume":"7","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Ghatnekar GS, Dix TA (2019) Diuretic activity of a novel peripherally-restricted orally-active kappa opioid receptor agonist. Med Sci (Basel) 7(9):93. https:\/\/doi.org\/10.3390\/medsci7090093","journal-title":"Med Sci (Basel)"},{"key":"1497_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.05.025","volume":"856","author":"TC Beck","year":"2019","unstructured":"Beck TC, Reichel CM, Helke KL, Bhadsavle SS, Dix TA (2019) Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats. Eur J Pharmacol 856:172396. https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.025","journal-title":"Eur J Pharmacol"},{"key":"1497_CR70","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fphar.2018.01388","volume":"9","author":"H Machelska","year":"2018","unstructured":"Machelska H, Celik MO (2018) Advances in achieving opioid analgesia without side effects. Front Pharmacol 9:1388. https:\/\/doi.org\/10.3389\/fphar.2018.01388","journal-title":"Front Pharmacol"},{"issue":"6","key":"1497_CR71","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/0031-9384(92)90479-l","volume":"52","author":"MD Lee","year":"1992","unstructured":"Lee MD, Clifton PG (1992) Free-feeding and free-drinking patterns of male rats following treatment with opiate kappa agonists. Physiol Behav 52(6):1179\u20131185. https:\/\/doi.org\/10.1016\/0031-9384(92)90479-l","journal-title":"Physiol Behav"},{"issue":"2","key":"1497_CR72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neuron.2009.12.024","volume":"65","author":"DJ Lyons","year":"2010","unstructured":"Lyons DJ, Horjales-Araujo E, Broberger C (2010) Synchronized network oscillations in rat tuberoinfundibular dopamine neurons: switch to tonic discharge by thyrotropin-releasing hormone. Neuron 65(2):217\u2013229. https:\/\/doi.org\/10.1016\/j.neuron.2009.12.024","journal-title":"Neuron"},{"issue":"7547","key":"1497_CR73","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nature14108","volume":"520","author":"Y Oka","year":"2015","unstructured":"Oka Y, Ye M, Zuker CS (2015) Thirst driving and suppressing signals encoded by distinct neural populations in the brain. Nature 520(7547):349\u2013352. https:\/\/doi.org\/10.1038\/nature14108","journal-title":"Nature"},{"issue":"7622","key":"1497_CR74","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nature18950","volume":"537","author":"CA Zimmerman","year":"2016","unstructured":"Zimmerman CA, Lin YC, Leib DE, Guo L, Huey EL, Daly GE, Chen Y, Knight ZA (2016) Thirst neurons anticipate the homeostatic consequences of eating and drinking. Nature 537(7622):680\u2013684. https:\/\/doi.org\/10.1038\/nature18950","journal-title":"Nature"},{"issue":"2","key":"1497_CR75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0014-4886(67)90139-2","volume":"17","author":"GJ Mogenson","year":"1967","unstructured":"Mogenson GJ, Stevenson JA (1967) Drinking induced by electrical stimulation of the lateral hypothalamus. Exp Neurol 17(2):119\u2013127. https:\/\/doi.org\/10.1016\/0014-4886(67)90139-2","journal-title":"Exp Neurol"},{"issue":"1","key":"1497_CR76","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1152\/ajplegacy.1958.193.1.230","volume":"193","author":"SD Morrison","year":"1958","unstructured":"Morrison SD, Barrnett RJ, Mayer J (1958) Localization of lesions in the lateral hypothalamus of rats with induced adipsia and aphagia. Am J Physiol 193(1):230\u2013234. https:\/\/doi.org\/10.1152\/ajplegacy.1958.193.1.230","journal-title":"Am J Physiol"},{"issue":"2","key":"1497_CR77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1037\/h0077202","volume":"90","author":"EM Stricker","year":"1976","unstructured":"Stricker EM (1976) Drinking by rats after lateral hypothalamic lesions: a new look at the lateral hypothalamic syndrome. J Comp Physiol Psychol 90(2):127\u2013143. https:\/\/doi.org\/10.1037\/h0077202","journal-title":"J Comp Physiol Psychol"},{"key":"1497_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac153","author":"H Ito","year":"2022","unstructured":"Ito H, Navratilova E, Vagnerova B, Watanabe M, Kopruszinski C, Moreira de Souza LH, Yue X, Ikegami D, Moutal A, Patwardhan A, Khanna R, Yamazaki M, Guerrero M, Rosen H, Roberts E, Neugebauer V, Dodick DW, Porreca F (2022) Chronic pain recruits hypothalamic dynorphin\/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain. https:\/\/doi.org\/10.1093\/brain\/awac153","journal-title":"Brain"},{"key":"1497_CR79","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fnins.2015.00466","volume":"9","author":"EH Chartoff","year":"2015","unstructured":"Chartoff EH, Mavrikaki M (2015) Sex differences in kappa opioid receptor function and their potential impact on addiction. Front Neurosci 9:466. https:\/\/doi.org\/10.3389\/fnins.2015.00466","journal-title":"Front Neurosci"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01497-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01497-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T23:04:20Z","timestamp":1664492660000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01497-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01497-7","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"12 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data in this manuscript were collected from animals and the study was approved by the Ethics Committee for Animal Experimentation of University of Arizona.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Caroline M. Kopruszinski, Robson Vizin, Moe Watanabe, Ashley L. Martinez and Luiz Henrique Moreira de Souza declare no personal, financial, or relational conflicts of interest with this work. David W. Dodick reports the following conflicts within the past 12\u00a0months: Consulting: AEON, Amgen, Clexio, Cerecin, Ctrl M, Allergan, Alder, Biohaven, Linpharma, Lundbeck, Promius, Eli Lilly, eNeura, Novartis, Impel, Satsuma, Theranica, Vedanta, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Revance, Equinox. Honoraria: CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, MJH Lifesciences, Miller Medical Communications, Southern Headache Society (MAHEC), WebMD Health\/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Research Support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI). Stock Options\/Shareholder\/Patents\/Board of Directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (Options), Theranica (Options), Second Opinion\/Mobile Health (Options), Epien (Options\/Board), Nocira (options), Matterhorn (Shares\/Board), Ontologics (Shares\/Board), King-Devick Technologies (Options\/Board), Precon Health (Options\/Board). Patent 17189376.1\u20131466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis.Frank Porreca has served as a consultant or received research funding from Voyager, SiteOne Therapeutics, Nektar, Amgen, Acadia, Blackthorn, Teva, Eli Lilly, Hoba, Allergan, Ipsen, and Proximagen and has served as a founder of Catalina Pharma, Scientific Advisory Board Regulonix, and Condor Pharma. Edita Navratilova has served as a consultant for Allergan.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}